Pfizer announces two-in-one vaccine for Covid AND flu

Pfizer is testing a new two-in-one vaccine targeting both Covid and flu amid sluggish uptake of its booster shot.

The first patient was inoculated with the vaccine this week in early clinical trials, with a total of 180 patients expected to get the dose.

Using mRNA technology popularized over the Covid pandemic, the shot targets BA.4 and BA.5 variants as well as four strains of the flu.

Vaccine maker Moderna is also testing a vaccine targeting Covid and flu, as well as one for these viruses and RSV — behind America’s winter wave. None are expected to be ready for this year’s flu season.

Uptake of the updated bivalent booster vaccine is lagging in the US, with just a handful of Americans who are eligible coming forward.

The pharmaceutical giant said the first patient was given a dose this week in the early stage trails that will run for six months (file photo)

Pfizer revealed that the first patient was injected in its Phase 1 trials — the earliest clinical trials — this week.

These tests are to ensure the vaccine is safe and effective, but the new vaccine will need to go throughmore tests before it can be rolled out nationwide.

The trial has recruited 180 people in the US who are between 18 and 64 years old and will be followed for six months.

Annaliesa Anderson, chief scientific officer in vaccine research and development at Pfizer, said mRNA technology was ‘well suited’ to tackling other viruses.

‘Pfizer is deeply proud of our continued work to explore its potential to protect against influenza and Covid in one combination vaccine,’ she said.

‘We think [this] could simplify immunisation practices against these two respiratory pathogens, potentially leading to better vaccine uptake for both diseases.

‘Even with existing seasonal influenza vaccines, the burden of this virus is severe across the world causing thousands of deaths and hospitalisations every year.’